CUE (Cue Biopharma) FFO


CUE Cue Biopharma Inc CUE
59 GF Score
Price $26.01
GF Value $62.11
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma FFO?

FFO (Funds from operations) only applies to REITs.

CUE
59GF Score
Cue Biopharma Inc CUE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $26.01 is trading 58.1% below its estimated GF Value™ of $62.11. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • FFO:
  • GF Value™: $62.11 vs. price of $26.01 (58.1% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score

Get the complete analysis for CUE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.01
Price
$62.11
GF Value